Sun Pharma Backs First U.S. Standardized Treatment Guidelines for Severe Alopecia Areata

Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) said on September 23, 2026, that it supports the first standardized U.S. treatment recommendations for adults with severe alopecia areata, which have been published in JAMA Dermatology. The guidelines establish a uniform clinical framework for treating severe AA, a condition marked by extensive hair loss. Standardization of care protocols may influence prescribing patterns and market access for approved therapies. Sun Pharma did not disclose financial terms or specify any products linked to the recommendations. The company's involvement signals its positioning in the dermatology segment, where treatment adoption often follows formal guideline publication.